Thank you.
Mr. Ambassador, with respect to the TRIPS discussions that are ongoing at the WTO, could you perhaps elaborate on what you are hearing, both on waiver performance and from industry?
We in this committee have heard testimony from various Canadian industries, research organizations and pharmaceutical companies, as well as several experts, indicating that there may be a risk to our own Canadian biomanufacturing industry by virtue of the fact that we would be introducing uncertainty into what is otherwise a very well-known playing field.
Mr. Ambassador, in your view, is that a risk that this committee should be concerned about?